Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke

NCT06995625 is registered in ClinicalTrials.gov with S&Ebio Co. Ltd. as lead sponsor.

NCT NCT06995625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06995625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke
Lead sponsor
S&Ebio Co. Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 22, 2026
Completion date
March 31, 2027
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke ais